Theravance Biopharma Files Preliminary Proxy for $17/Share Zymeworks Buyout — Vote Set, CVR Terms Detailed
TBPH sits 51% above its 52-week low of $11.2.
Summary
Theravance Biopharma filed its preliminary proxy for the $17/share cash-plus-CVR acquisition by Zymeworks, revealing a competitive sale process, management projections, and a fairness opinion. Shareholder vote date is pending.
Key Events · M&A and Partnerships · TBPH
-
Merger Background and Process
An extensive strategic review, launched in 2024, reached out to 60 potential counterparties. Final bids came in at $17.00 per share from Zymeworks and $16.80 from Party A. Zymeworks won out on higher deal certainty and fewer outstanding conditions.
-
Merger Consideration
Shareholders will receive $17.00 in cash plus one non-tradable CVR per share. The CVR entitles holders to 80% of net proceeds from any ampreloxetine license, divestiture, or monetization within 10 years, a $50 million milestone upon first commercial sale in major markets, and 10% of net sales royalties.
-
Fairness Opinion and Financial Projections
Lazard Freres rendered a fairness opinion, supported by a discounted cash flow analysis implying an equity value of $15.25–$16.25 per share. Management's standalone projections show declining revenue from $183M in 2026 to $9M by 2040, driven by YUPELRI loss of exclusivity.
-
Executive Compensation in Merger
CEO Rick Winningham could receive up to $8.8M in cash severance and accelerated equity, while other named executives could receive $3.2M–$3.2M. These are double-trigger payments upon termination following the merger.
Analysis · TBPH · Life Sciences
The preliminary proxy statement from Theravance Biopharma offers the first detailed account of the path to its $17 per share acquisition by Zymeworks. A broad strategic review reached out to 60 potential counterparties, and after a competitive bidding process against Party A, Zymeworks emerged as the winner. The deal includes a non-tradable contingent value right (CVR) tied to future monetization of ampreloxetine, which the board acknowledges is highly speculative. The proxy also discloses management's standalone financial projections, Lazard's fairness opinion, and the golden parachute compensation for executives. With the HSR waiting period already terminated, the main remaining hurdle is shareholder approval. The $17 cash offer represents a 22% premium to the stock price before the failed Phase 3 CYPRESS study results were announced, but the CVR component adds uncertainty. The detailed background shows the board explored multiple alternatives, including a sale of YUPELRI or a return of capital, before concluding a whole-company sale was the best path.
At the time of this filing, TBPH was trading at $16.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $876.4M. The 52-week trading range was $11.20 to $21.03. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.